UPDATE – Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223
27 mars 2024 08h34 HE
|
TellBio, Inc
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for radium-223...
Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-2230
27 mars 2024 08h00 HE
|
TellBio, Inc
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for...
TellBio Announces Consecutive Manuscripts Showcasing Promising Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Tailoring Therapy in Advanced Breast Cancer
06 juil. 2023 09h19 HE
|
TellBio, Inc
-- Prostate Circulating Tumor Cells Isolated with TellDx Technology Demonstrates Epigenetic Changes that Silence Immune Surveillance Genes and Spare Proliferation-Associated Genes -- -- Breast Cancer...
Circulating Tumor Cells Isolated with Unique TellDx Technology May Help Predict Response to Therapy in Patients with Progressive Metastatic Breast Cancer
22 mai 2023 08h00 HE
|
TellBio, Inc
-- CTCs isolated with TellDx leveraged to assess sensitivity and potential clinical benefit from an alternative tolerable therapeutic option in a select cohort of patients with metastatic breast...
Isolation of Circulating Tumor Cells with TellDx Platform Reveals Potential Mechanism of Resistance to Immune Checkpoint Blockade in Melanoma
16 mars 2023 08h00 HE
|
TellBio, Inc
--Interrogation of circulating tumor cells (CTCs) shows downregulation of KEAP1 gene promotes resistance to immune checkpoint blockade in melanoma-- --Study provides valuable insights into the...
Reduction in Circulating Tumor Cells (CTC), Enriched by TellBio Platform, with Novel Dual-Cadherin Antibody (23C6) Results in Significant Metastasis Suppression
24 oct. 2022 08h00 HE
|
TellBio, Inc
-- TellDx CTC System can be leveraged to monitor efficacy of novel therapeutic agents— --Targeting multiple cadherins with 23C6 can ameliorate cancer metastasis-- -- TellBio has exclusive...
Circulating Tumor Cell (CTC) Isolation with TellDx Technology Could Inform Personalized Drug Treatment in Prostate Cancer
20 janv. 2022 16h42 HE
|
TellBio, Inc
-- Single-cell proteomics can elucidate kinase activity in prostate cancer models -- -- Kinase activity in bone metastases and epithelial circulating tumor cells is elevated -- BEVERLY, Mass., Jan. ...
TellBio’s Scientific Founders Publish Very High Concordance between CTCs and ctDNA from Liquid Biopsies in Patients with Breast Cancer
15 juil. 2021 08h00 HE
|
TellBio, Inc
--Rare parallel analyses of directly matched CTCs, utilizing TellBio’s TellDx platform, and ctDNA samples showing 95% concordance published in Breast Cancer Research and Treatment-- --Isolation of...
TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer
10 mai 2021 07h00 HE
|
TellBio, Inc
--Closes $5 million Series A financing-- --Appoints Pritesh J. Gandhi, PharmD, as Chief Executive Officer and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations-- ...